naa a22 4500 51076455X CHVBK 20180411083152.0 cr unu---uuuuu 180411e20131101xx s 000 0 eng 10.1007/s12094-013-1071-8 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1071-8 Epstein R. Department of Oncology, Clinical Cancer Informatics & Research Centre, The Kinghorn Cancer Centre, Sydney, Australia aut Has discovery-based cancer research been a bust? [Elektronische Daten] [R. Epstein] The completion of the human genome sequence sparked optimism about prospects for new anticancer drug development, but clinical progress over the last decade has proven slower than expected. Here it is proposed that unrealistically high expectations of first-generation discovery-based diagnostics have contributed to this problem. Hypothesis-based single-molecule tests (e.g., mutation screening of KRAS, EGFR, BRAF or KIT genes) continue to change clinical practice incrementally, whereas first-generation multiplex assays—such as gene expression profiling and proteomics—have identified few high-impact therapeutic targets despite numerous correlations with prognosis. To move forward, second-generation multiplex diagnostics should be based not on statistical patterns/associations alone, but on clinically interpretable (‘high-signal-to-noise') data such as change-of-function mutations, gene amplifications, recurrent chromosomal anomalies, and abnormal phosphorylation profiles of ERK or mTOR signaling cascades. Federación de Sociedades Españolas de Oncología (FESEO), 2013 cDNA microarray nationallicence Proteomics nationallicence Pathway fingerprinting nationallicence Target-specific anticancer drug therapy nationallicence Personalized medicine nationallicence ER : Estrogen receptor nationallicence FDG-PET : Positron emission tomography using fluorodeoxyglucose nationallicence PR : Progesterone receptor nationallicence Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 865-870 1699-048X 15:11<865 2013 15 12094 https://doi.org/10.1007/s12094-013-1071-8 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1071-8 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Epstein R. Department of Oncology, Clinical Cancer Informatics & Research Centre, The Kinghorn Cancer Centre, Sydney, Australia aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 865-870 1699-048X 15:11<865 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer